Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Prostatic Neoplasms 6 Neoplasms by Site 2 Neoplasms 2 Neoplasm Metastasis 2 Breast Diseases 2 Skin Diseases 1 Salivary Gland Neoplasms 1 Ovarian Neoplasms 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Advanced Prostate Cancer 1

Interventions

Paclitaxel 113 Carboplatin 99 Bevacizumab 59 pembrolizumab 56 liposomal doxorubicin 56 Gemcitabine 42 olaparib 39 Topotecan 33 niraparib 29 Nivolumab 21 Cisplatin 21 Doxorubicin 17 Cyclophosphamide 17 1-dodecylpyridoxal 16 Drug Therapy 15 Docetaxel 15 avelumab 13 Fulvestrant 11 oregovomab 10 Oxaliplatin 10 rucaparib 9 fludarabine 9 Injections 9 Fluorouracil 9 veliparib 8 mirvetuximab soravtansine 8 atezolizumab 8 Cetuximab 8 fluzoparib 7 cemiplimab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Neoplasms × Gonadotropin-Releasing Hormone × Clear all

NCT04931342 2026-06-08

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡